Roche win boosts case for adding chemo to cancer immunotherapy

Lung cancer is by far the biggest oncology market and first-line treatment provides access to the most patients

Cancer doctors struggling to work out the best way to use modern immunotherapy drugs now have further evidence of the benefits of adding them to chemotherapy, despite earlier scepticism.
News that Roche's immune system-boosting drug Tecentriq delayed lung cancer progression when given alongside chemo and its older drug Avastin validates the approach for the first time in a large Phase III clinical trial.
It is a significant milestone for physicians, patients and investors, who are trying to assess the competitive landscape as drugmakers race to develop better ways to fight ...

This article is no longer available in our repository.

There could be multiple reasons for this.

You could try searching for this headline on the source website (reuters.com).